Karyopharm Therapeutics Inc. (KPTI) Stock Score, Valuation & Financial Research
Karyopharm Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 15/100.
Quick answer for KPTI
Karyopharm Therapeutics Inc. currently has a Wall Street Score of 15/100. The stored market price is $1.61. Its financial score is 7/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Karyopharm Therapeutics Inc. does
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensi
KPTI financial snapshot
- Wall Street Score:
- 15/100
- Current price:
- $1.61
- Market capitalization:
- $36.5M
- Revenue:
- $151.1M
- Net income:
- $-195.0M
- Free cash flow:
- $-75.4M
- Cash:
- $90.8M
- Total debt:
- $230.9M
- EPS:
- -17.93
- Financial score:
- 7/100
- Valuation score:
- 0/100
- Revenue score:
- 13/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-75.4M, showing cash burn in the current stored period.
- The balance sheet shows $90.8M of cash versus $230.9M of total debt, so leverage deserves attention.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 7/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research KPTI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.